Clinical study on oral administration of Sanyi Le active lactic acid bacteria powder to improve abnormal lipid metabolism in PCOS patients: a multicenter prospective clinical cohort study

Start Date01 Aug 2024

Sponsor / Collaborator

Zhejiang Provincial Peoples Hospital

JPRN-UMIN000052474 / Suspended

A study to evaluate the effects of capsules containing lactic acid bacteria on improving knee joint symptoms - A study to evaluate the effects of capsules containing lactic acid bacteria on improving knee joint symptoms

Start Date04 Jan 2024

Sponsor / Collaborator

MEGMILK SNOW BRAND Co., Ltd.

NCT06327581 / RecruitingNot ApplicableIIT

Comparative Study of Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata

Alopecia areata (AA) is an immunologically mediated disease characterized by non-scarring hair loss (Madni and Shapiro, 2000). AA is presented by rapid and complete hair loss in one or more round or oval patches, usually on the scalp, beard area, eyebrows, eyelashes, and less commonly, on other hairy areas of the body (Berker et al., 2010 and James et al., 2011) Alopecia areata is a T-cell-mediated autoimmune disease. There is a complicated interplay between loss of immune privilege in the hair follicle, autoimmune-mediated hair follicle damage, and activation of inflammatory pathways that have been argued to explain the development of this disorder, but the exact pathophysiology of AA remains unknown. Hair follicles are infiltrated by autoreactive CD8 and CD4 T lymphocytes, which attack hair follicle-derived autoantigens while sparing the stem compartment (Rajabi et al., 2018).
Alopecia areata can be treated with topical and/or intralesional corticosteroids, which are the treatment of choice. Anthralin, minoxidil, coal tar, and topical immunotherapy are examples of other topical treatments. Systemic immunosuppressants such as cyclosporine, systemic steroids, Janus kinase inhibitors, and methotrexate may be considered in severe resistant cases (lee and lee, 2017).
Intralesional triamcinolone acetonide is preferred in cases of AA , as it is well known as anti-inflammatory and interferes with local immunity of the skin, which helps in the recovery of the disease, but if used in wrong technique or given in a high dose, it might cause all the side effects of corticosteroid, especially skin atrophy (Berker et al., 2010).
Lactic acid is a member of alpha-hydroxy acids. It has been used in the treatment of many skin diseases, like AA and vitiligo. Lactic acid stimulates spontaneous secretion of vascular endothelial growth factor (VEGF) by human reconstructed epidermis. VEGF is an angiogenic cytokine involved in angiogenesis and wound healing and stimulates the growth of hair follicles resulting in recovery of AA. Other studies suggest that lactic acid may act through its irritant effect (Al-Tammimy, 2005).
Vitamin D interacts with the innate and adaptive immune systems in a variety of ways, the majority of which contribute to its downregulation (Nancy and Yehuda, 2009). It has a powerful effect on T and B lymphocytes, influencing their activation responses (Arnson et al., 2007).
All cells of the immune system express 1,25-dihydroxyvitamin D3 receptors (VDRs) and are therefore vulnerable to calcitriol-mediated modulation. Vitamin D3 has the ability to influence the migration and maturation of different dendritic cell subtypes and their production of chemokines and cytokines, giving them an immunoregulatory and tolerogenic role (Illescas-Montes et al., 2019) It has been shown that VDRs are highly expressed in the keratinocytes of human hair follicles and the absence of their expression is associated with reduced hair follicle growth and epidermal differentiation. Reduced VDR expression in the hair follicles of affected areas has also been observed in studies of AA patients' scalp (Çerman et al., 2015).
Microneedling (MN) is a technique that comprises puncturing the skin repeatedly with sterile microneedles (Iriarte et al., 2017). It promotes hair regeneration by triggering stem cells in the hair bulge, which results in the generation of growth factors. It also improves blood circulation to the hair follicles and influences the local immune cells (Chandrashekar et al., 2014). Moreover, combining MN with applied topical drugs facilitates their absorption through the microchannels created within the epidermis (Fertig et al., 2018).

Start Date15 Dec 2023

Sponsor / Collaborator

Zagazig University

100 Clinical Results associated with Lactic acid

100 Translational Medicine associated with Lactic acid

100 Patents (Medical) associated with Lactic acid

3,642

Literatures (Medical) associated with Lactic acid

01 Feb 2025·Journal of Environmental Sciences

Comprehensive metabolic profiling of dioxin-like compounds exposure in laying hens: Implications for toxicity assessment

Article

Author: Zhang, Qian ; Chen, Yangsheng ; Wang, Pu ; Hu, Xiaoxu ; Xu, Li ; Xie, Heidi Qunhui ; Tang, Lijuan ; Zhao, Bin ; Xu, Tong ; Dong, Shujun ; Zheng, Liping ; Wang, Chu ; Zhang, Qinghua ; Zhang, Su ; Wang, Ruiguo

The evaluation of toxicity related to polychlorinated dibenzo-p-dioxins and furans (PCDD/Fs) and dioxin-like polychlorinated biphenyls (DL-PCBs) is crucial for a comprehensive risk assessment in real-world exposure scenarios. This study employed a controlled feeding experiment to investigate the metabolic effects of dioxin-like compounds (DLCs) on laying hens via feed exposure. Diets enriched with two concentrations (1.17 and 5.13 pg toxic equivalents (TEQ)/g dry weight (dw)) were administered over 14 days, followed by 28 days of clean feed. Metabolomics analyses of blood samples revealed significant metabolic variations between PCDD/Fs and DL-PCBs exposed groups and controls, reflecting the induced metabolic disruption. Distinct changes were observed in sphingosine, palmitoleic acid, linoleate, linolenic acid, taurocholic acid, indole acrylic acid, and dibutyl phthalate levels, implying possible connections between PCDD/Fs and DL-PCBs toxic effects and energy-neuronal imbalances, along with lipid accumulation and anomalous amino acid metabolism, impacting taurine metabolism. Moreover, we identified three differential endogenous metabolites-L-tryptophan, indole-3-acetaldehyde, and indole acrylic acid-as potential ligands for the aryl hydrocarbon receptor (AhR), suggesting their role in mediating PCDD/Fs and DL-PCBs toxicity. This comprehensive investigation provides novel insights into the metabolic alterations induced by PCDD/Fs and DL-PCBs in laying hens, thereby enhancing our ability to assess risks associated with their exposure in human populations.

01 Dec 2024·Molecular Biology Reports

Employing novel biocompatible composite scaffolds with bioglass 58S and poly L-lactic acid for effective bone defect treatment

Article

Author: Mayvani, Mohanna Akbarin ; Motalebzadeh, Erfan ; Ghollasi, Marzieh ; Hemati, Saideh

BACKGROUNDBioglass materials have gained significant attention in the field of tissue engineering due to their osteoinductive and biocompatible properties that promote bone cell differentiation. In this study, a novel composite scaffold was developed using a sol-gel technique to combine bioglass (BG) 58 S with a poly L-lactic acid (PLLA).METHODS AND RESULTSThe physiochemical properties, morphology, and osteoinductive potential of the scaffolds were investigated by X-ray diffraction analysis, scanning electron microscopy, and Fourier-transform infrared spectroscopy. The results showed that the SiO₂-CaO-P₂O₅ system was successfully synthesized by the sol-gel method. The PLLA scaffolds containing BG was found to be osteoinductive and promoted mineralization, as demonstrated by calcium deposition assay, upregulation of alkaline phosphatase enzyme activity, and Alizarin red staining data.CONCLUSIONSThese in vitro studies suggest that composite scaffolds incorporating hBMSCs are a promising substitute material to be implemented in bone tissue engineering. The PLLA/BG scaffolds promote osteogenesis and support the differentiation of bone cells, such as osteoblasts, due to their osteoinductive properties.

01 Dec 2024·Cellular and Molecular Life Sciences

Lactic acid promotes nucleus pulposus cell senescence and corresponding intervertebral disc degeneration via interacting with Akt

Article

Author: Qi, Yuhan ; Chen, Yuxuan ; Zhang, Yang ; Li, Haiyin ; Li, Changqing ; Liu, Libangxi ; Zhai, Yu ; Chang, Xian ; Hu, Zhilei ; Feng, Chencheng ; Li, Yueyang ; Lou, Jinhui ; Liu, Chao ; Zhou, Yue ; Zhang, Yuyao

The accumulation of metabolites in the intervertebral disc is considered an important cause of intervertebral disc degeneration (IVDD). Lactic acid, which is a metabolite that is produced by cellular anaerobic glycolysis, has been proven to be closely associated with IVDD. However, little is known about the role of lactic acid in nucleus pulposus cells (NPCs) senescence and oxidative stress. The aim of this study was to investigate the effect of lactic acid on NPCs senescence and oxidative stress as well as the underlying mechanism. A puncture-induced disc degeneration (PIDD) model was established in rats. Metabolomics analysis revealed that lactic acid levels were significantly increased in degenerated intervertebral discs. Elimination of excessive lactic acid using a lactate oxidase (LOx)-overexpressing lentivirus alleviated the progression of IVDD. In vitro experiments showed that high concentrations of lactic acid could induce senescence and oxidative stress in NPCs. High-throughput RNA sequencing results and bioinformatic analysis demonstrated that the induction of NPCs senescence and oxidative stress by lactic acid may be related to the PI3K/Akt signaling pathway. Further study verified that high concentrations of lactic acid could induce NPCs senescence and oxidative stress by interacting with Akt and regulating its downstream Akt/p21/p27/cyclin D1 and Akt/Nrf2/HO-1 pathways. Utilizing molecular docking, site-directed mutation and microscale thermophoresis assays, we found that lactic acid could regulate Akt kinase activity by binding to the Lys39 and Leu52 residues in the PH domain of Akt. These results highlight the involvement of lactic acid in NPCs senescence and oxidative stress, and lactic acid may become a novel potential therapeutic target for the treatment of IVDD.

News (Medical) associated with Lactic acid

28 Aug 2024

·www.prnewswire.com

The Chemical Peel Market is projected to grow by USD 814.4 million from 2024 to 2028, driven by rising demand for aesthetic treatments and technological advancements, AI-powered report- Technavio

NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global chemical peel market size is estimated to grow by USD 814.4 millionn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.19% during the forecast period. Increasing demand for aesthetic procedures and technological advancement is driving market growth, with a trend towards increasing awareness about anti-aging measures. However, high cost of chemical peel products poses a challenge. Key market players include AbbVie Inc., AMOREPACIFIC Group Inc., Bausch Health Companies Inc., BeautyPharmaCo, Candela Corp., Caudalie International SE, Galderma SA, Hale Cosmeceuticals Inc, Image International Manufacturing LLC, Johnson and Johnson Services Inc., LOreal SA, MedPeel, Merz Pharma GmbH and Co KGaA, NEFTIS LABORATORIOS SL, Pierre Fabre SA, ProDerma Light, Radius Healthcare Pvt. Ltd., Renee Rouleau Inc., Topix Pharmaceuticals Inc., and Unilever PLC. Continue Reading Technavio has announced its latest market research report titled Global chemical peel market 2024-2028 Get a detailed analysis on regions, market segments, customer landscape, and companies - Click for the snapshot of this report Key Market Trends Fueling Growth The chemical peel market is experiencing significant growth due to the increasing awareness and demand for anti-aging procedures. In 2021 and 2022, there has been a rise in the number of cosmetic procedures performed in countries like the US, Brazil, Mexico, Germany, and Spain. This trend is driven by the advantages of chemical peels, including age spot reduction, sun damage removal, skin lightening, smoothening, and improved collagen growth. Vendors are actively promoting these benefits through various channels, such as websites, conferences, and magazine advertisements. Moreover, the increasing per capita income and economic development in emerging economies, particularly India and China, have led to a surge in online research and comparisons of various procedures. As a result, the chemical peel market is poised for continued growth during the forecast period. The Chemical Peel Market is witnessing significant growth due to the increasing demand for non-surgical skincare solutions. Trichloroacetic acid and Jessner's Solution are popular peeling agents used in chemical resurfacing for improving skin texture, reducing hyperpigmentation, acne scars, fine lines, and wrinkle reduction. These treatments are effective for sun damage, melasma treatment, and acne treatment. Medical aesthetics and cosmeceutical treatments using chemical formulations offer clinical benefits for various skin conditions. Glytone, Alpha hydroxy acid (AHA), sugar cane, sugar beets, lactic peel, milk, and Alpha-hydroxy acids (AHAs) are common peeling agents. Medium peels target the epidermis and dermis layers for enhanced skin health and beauty. The chemical peel procedure is a dermatologic treatment for skin health improvement and aesthetic enhancement. Discover a Comprehensive 360° Market Analysis: Understand the Impact of AI. For detailed information- Request Sample! Market Challenges The chemical peel market is currently facing a growth challenge due to the high cost of treatments, which is limiting its adoption, particularly in developing countries. The average price for a chemical peel ranges from USD600 to USD900, with significant variations depending on the type of peel. Light peels cost as low as USD150 but require multiple sessions for optimal results, while medium and deep peels can cost up to USD6,000. These high costs include fees for the chemical peel procedure, anesthesia, and operating room. The monopolistic approach of vendors, such as Allergan plc, in the market further contributes to the lack of competitive pricing. Allergan, a leading player in medical aesthetics, has acquired most of the market share, targeting high-income and upper-middle-class consumers. As a result, the inability of middle and lower-middle-class individuals to afford these costly procedures is hindering the growth of the global chemical peel market. The Chemical Peel market is thriving in the Skincare and Aesthetics industries, providing solutions for common concerns such as Acne, Pigmentation, and Wrinkle issues. Glytone's Peeling Solution, which contains Alpha Hydroxy Acids (AHAs) derived from Sugar Cane and Sugar Beets, is a popular choice for exfoliating the Epidermis. Medium Peels, using stronger Chemical Agents like TCA, reach deeper into the Dermis to address Acne spots, Dark Circles, and signs of Fatigue. Dermatology and Aesthetic Medicine professionals use these Dermatological Procedures for Skin Renewal, often combining different Chemical Compounds like Glycolic Acid, Lactic Acid, and Salicylic Acid for optimal results. The Beauty Industry continues to innovate with new Peeling Solutions, offering professional Chemical Exfoliation treatments for Facial Rejuvenation. For more insights on driver and challenges - Download a Sample Report Segment Overview This chemical peel market report extensively covers market segmentation by End-user 1.1 Hospital and recreation centers 1.2 Dermatology clinics Type 2.1 Light peel 2.2 Medium peel 2.3 Deep peel Geography 3.1 North America 3.2 Europe 3.3 APAC 3.4 South America 3.5 Middle East and Africa 1.1 Hospital and recreation centers- The Chemical Peel Market is experiencing steady growth due to increasing consumer awareness and demand for skin rejuvenation treatments. Businesses are offering various types of chemical peels to cater to diverse skin concerns, such as acne scars, aging, and sun damage. Market leaders are focusing on research and development to introduce innovative peel solutions and expand their customer base. Overall, the market is expected to continue its expansion in the coming years.For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 - 2022) - Download a Sample Report Research Analysis The Chemical Peel market encompasses a range of skincare treatments used in aesthetics to address various skin concerns, including acne, pigmentation, and wrinkle issues. These peels work by applying a chemical solution to the skin, causing it to exfoliate and peel off, revealing smoother, fresher skin. The solutions typically contain Alpha-hydroxy acids (AHAs) derived from fruits like glycolic acid from sugar cane and lactic peels from milk. Deeper peels may involve Phenol or Trichloroacetic acid, reaching the dermis for more significant results. Acne spots, dark circles, and signs of fatigue can also be targeted. Genetics and collagen production play a role in skin health, making chemical peels a popular choice for those seeking to improve their complexion in dermatology practices. Market Research Overview The Chemical Peel market encompasses a range of skincare treatments that utilize chemical solutions to improve the appearance of the skin. These peels are commonly used for various aesthetic concerns such as acne, pigmentation, and wrinkle issues. The solutions typically contain Alpha Hydroxy Acids (AHAs) derived from fruits like sugar cane and sugar beets, or Beta Hydroxy Acids (BHAs) like Salicylic Acid. The depth of the peel can vary from light to medium, affecting the epidermis or dermis layers. Chemical Peels are used to address acne spots, dark circles, fatigue, and signs of aging such as fine lines and wrinkles. The causes of these conditions can stem from genetics, sun damage, or lifestyle factors. The treatments promote collagen production, leading to skin renewal and texture improvement. Chemical Peels are considered a dermatological procedure and are also offered in aesthetic medicine clinics and the beauty industry. They provide a form of chemical exfoliation that goes beyond traditional cleansing methods. The solutions work by dissolving the bonds holding dead skin cells together, revealing smoother, healthier skin. Popular chemical peel formulations include Glytone, Jessner's Solution, TCA Peel, and various combinations of AHAs and BHAs. These treatments are administered as facial treatments in professional settings and are an essential part of medical aesthetics and cosmeceutical offerings. Chemical Peels contribute to skin health and beauty enhancement, addressing various skin conditions and concerns. They are an effective means of reducing hyperpigmentation, acne scars, sun damage, and melasma. The cosmetic procedure is a popular choice for individuals seeking wrinkle reduction and skin rejuvenation. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation End-user Hospital And Recreation Centers Dermatology Clinics Type Light Peel Medium Peel Deep Peel Geography North America Europe APAC South America Middle East And Africa 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

30 Jul 2024

·www.drugs.com

FDA Warns Against Purchasing or Using Chemical Peel Skin Products Without Professional Supervision

Audience: Consumer July 30, 2024 -- FDA is warning consumers not to purchase or use certain chemical peel skin products without appropriate professional supervision due to risk of serious skin injuries. The agency has not approved any chemical peel products, and consumers should only consider using chemical peel products under the supervision of a dermatologist or licensed and trained practitioner. Many of these chemical peel products are sold in beauty product stores and online and marketed for purposes such as acne, discoloration, wrinkles, and collagen production. They contain ingredients such as trichloroacetic acid (TCA), glycolic acid, salicylic acid and lactic acid in varying concentrations that are too high to be used safely at home without supervision by a dermatologist or other licensed and trained practitioner. Using products that contain high concentrations of these acids may lead to serious injury from chemical burns. The concentration, number of applications, and length of time a chemical peel product is left on the skin all influence how deeply it can penetrate skin layers and potentially lead to chemical burns. These products remove layers of skin to varying depths and may cause severe chemical burns, pain, swelling, infection, skin color changes, and disfiguring scars. These injuries may even require emergency care or specialty care from a dermatologist or surgeon. FDA has issued warning letters to the following companies for selling these products: FDA encourages health care professionals and consumers to report adverse events or quality problems with these or any medications to FDA’s MedWatch Adverse Event Reporting program: Source: FDA Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

15 Jul 2024

·www.prnewswire.com

Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC

MUMBAI, India and NAPLES, Fla. and SAN DIEGO, July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women's Health. Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections. Continue Reading Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC Under the terms of the deal, Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones. Dr. Fabrice Egros, President - Global Corporate Development, Lupin, said, "We are very pleased to divest our U.S. Commercial Women's Health Specialty business, including SOLOSEC®, to Evofem. This divestment is another step in aligning our U.S. specialty business with our strategic plan to build our specialty business in therapeutic areas where we have building blocks of synergy. These include respiratory and neurological diseases." "The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women's daily lives. SOLOSEC is a commercially attractive, single-dose oral antibiotic that addresses two pervasive sexual health infections. We can now fully leverage our commercial infrastructure, maximize our strong physician relationships, and re-launch an asset with tremendous growth potential," said Saundra Pelletier, Chief Executive Officer, Evofem. About Lupin Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector. Please visit for more information. Follow us on: LinkedIn: Facebook: X (f/k/a Twitter): About Evofem Biosciences Evofem Biosciences is focused on commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com. In December 2023, Evofem entered into a Merger Agreement with Aditxt, Inc. (Nasdaq: ADTX) under which Aditxt intends to acquire Evofem. The parties reinstated and amended the Merger Agreement, as amended, in May 2024 and are working to close the contemplated transaction in the second half of 2024. Follow us on: LinkedIn: Facebook: X (f/k/a Twitter): About SOLOSEC® SOLOSEC® (secnidazole) 2 g oral granules is the first and only single-dose oral prescription approved to treat both bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and trichomoniasis, a sexually transmitted infection, in people 12 years of age and older.1-4 Since trichomoniasis is a sexually transmitted infection, sexual partners of infected patients should be treated with the same dose and at the same time to prevent reinfection. SOLOSEC® is designed to be easy to take and one oral dose contains a complete course of treatment.[1] Additional information about SOLOSEC® can be found at . References: 1 SOLOSEC Package Insert 2 Workowski KA, Bachmann LH, Chan PA, et al. CDC Sexually Transmitted Diseases Treatment Guidelines, 2001. MMWR Recomm Rep 2021; 70(RR-04):1-192. 3 Onderdonk AB, Delaney ML, Fichorova RN. The Human Microbiome During Bacterial Vaginosis. Clin Microbiol Rev. 2016;29(2):223-238. 4 Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-869. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the anticipated timing to close the contemplated Aditxt transaction. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in Evofem's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 27, 2024, Quarterly Report on Form 10-Q for the three months ended March 31, 2024 filed with the SEC on May 12, 2024, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem does not undertake any duty to update any forward-looking statement except as required by law. Photo: Logo: SOURCE Lupin Limited

Drug ApprovalAcquisition

100 Deals associated with Lactic acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00111	-	G01AD01	DB04398

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intervertebral Disc Disease	Phase 2	ES	Stayble Therapeutics AB	31 Jul 2020
Intervertebral Disc Disease	Phase 2	RU	Stayble Therapeutics AB	31 Jul 2020
Intervertebral Disc Disease	Phase 2	NL	Stayble Therapeutics AB	31 Jul 2020
Low Back Pain	Phase 2	NL	Stayble Therapeutics AB	31 Jul 2020
Low Back Pain	Phase 2	RU	Stayble Therapeutics AB	31 Jul 2020
Low Back Pain	Phase 2	ES	Stayble Therapeutics AB	31 Jul 2020
Pain	Preclinical	ES	Stayble Therapeutics AB	31 Jul 2020
Pain	Preclinical	NL	Stayble Therapeutics AB	31 Jul 2020
Pain	Preclinical	RU	Stayble Therapeutics AB	31 Jul 2020
Vascular Calcification	Preclinical	CN	Southeast University	18 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EADV2023	Not Applicable	Acne Vulgaris	60	16.7% salicylic acid and 16.7% lactic acid in collodion base	udkpzatfex(uxxzlgmwox) = Mild burning, erythema and exfoliation was seen in 31.6% of patients kgxbnwuvlm (tdtixgqhxh )	Positive	11 Oct 2023
ASCO2004	Not Applicable	Recurrent Cervical Cancer	64	Water	dzxthzgooi(czpybcjmpq) = xqpqjzhheq hvjqjdxfht (lajdgyjhon ) View more	-	15 Jul 2004
ASCO2004	Not Applicable	Recurrent Cervical Cancer	64	Povidone-iodine	qlqfrgojme(pzqsmrjysg) = dmvdclhrou pfxewbcraj (wjgumzkgwd ) View more	-	15 Jul 2004

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis